MA42137A - Anticorps vhb anti-pre-s1 - Google Patents
Anticorps vhb anti-pre-s1Info
- Publication number
- MA42137A MA42137A MA042137A MA42137A MA42137A MA 42137 A MA42137 A MA 42137A MA 042137 A MA042137 A MA 042137A MA 42137 A MA42137 A MA 42137A MA 42137 A MA42137 A MA 42137A
- Authority
- MA
- Morocco
- Prior art keywords
- vhb
- antibody
- vhb antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015079534 | 2015-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42137A true MA42137A (fr) | 2021-04-07 |
Family
ID=57392535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042137A MA42137A (fr) | 2015-05-22 | 2016-05-23 | Anticorps vhb anti-pre-s1 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20180094047A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3978521A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6820278B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102770671B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN113527470B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2896275T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1243429A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA42137A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2739955C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016188386A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102770671B1 (ko) | 2015-05-22 | 2025-02-24 | 화후이 헬스 리미티드 | 항-Pre-S1 HBV 항체 |
| WO2019204462A2 (en) | 2018-04-17 | 2019-10-24 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
| JP7454855B2 (ja) * | 2018-12-21 | 2024-03-25 | 国立大学法人広島大学 | 抗ｐｒｅＳ１抗体およびその用途 |
| WO2021013135A1 (en) * | 2019-07-20 | 2021-01-28 | Huahui Health Ltd. | A method of treating hbv infection by using anti-pre-s1 hbv antibodies |
| JP2024525184A (ja) * | 2021-06-15 | 2024-07-10 | アピットバイオ， インク． | Ｂ型肝炎ウイルスｐｒｅＳ１抗原の肝細胞受容体結合部位に特異的に結合するヒト抗体及びその用途 |
| WO2023039243A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use |
| CN116568808A (zh) * | 2021-10-19 | 2023-08-08 | 北京三诺佳邑生物技术有限责任公司 | 特异性结合乙型肝炎病毒表面抗原pre-S1的抗体及其应用 |
| CN114685663B (zh) * | 2022-04-07 | 2023-09-08 | 西南大学 | 一种抗胆固醇依赖性细胞溶素的抗体及其应用 |
| CN117304308A (zh) * | 2022-06-20 | 2023-12-29 | 华辉安健（北京）生物科技有限公司 | 抗乙型肝炎病毒的抗体及其制备和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| CA2041772A1 (en) * | 1990-05-11 | 1991-11-12 | Larry T. Mimms | Monoclonal antibodies to pres2 and pres1 polypeptide of the hepatitis b viral envelope |
| ATE207119T1 (de) * | 1992-11-06 | 2001-11-15 | Sandoz Ltd | Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind |
| KR100345463B1 (ko) | 1998-11-19 | 2003-01-08 | 주)녹십자 | B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법 |
| CN1216914C (zh) * | 2000-05-17 | 2005-08-31 | 韩国科学技术研究院 | 对hbv表面抗原pre－s1具有特异性的人源化抗体 |
| KR100423614B1 (ko) * | 2001-05-16 | 2004-03-22 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
| EP1281761A1 (en) * | 2001-07-27 | 2003-02-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof. |
| US7601351B1 (en) * | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| CN1733798B (zh) * | 2005-08-12 | 2012-07-04 | 上海贺普生物科技有限公司 | 乙型肝炎病毒表面l蛋白相关肽 |
| WO2011045079A1 (en) * | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| CN109354623B (zh) * | 2012-04-25 | 2022-06-24 | 华辉安健（北京）生物科技有限公司 | 乙肝肝炎病毒功能性受体的组成以及相关应用 |
| KR102770671B1 (ko) | 2015-05-22 | 2025-02-24 | 화후이 헬스 리미티드 | 항-Pre-S1 HBV 항체 |
-
2016
- 2016-05-23 KR KR1020177036711A patent/KR102770671B1/ko active Active
- 2016-05-23 WO PCT/CN2016/082985 patent/WO2016188386A1/en not_active Ceased
- 2016-05-23 ES ES16799274T patent/ES2896275T3/es active Active
- 2016-05-23 CN CN202110657776.0A patent/CN113527470B/zh active Active
- 2016-05-23 CN CN201680029377.7A patent/CN107614525B/zh active Active
- 2016-05-23 RU RU2017145085A patent/RU2739955C2/ru active
- 2016-05-23 HK HK18102836.4A patent/HK1243429A1/zh unknown
- 2016-05-23 JP JP2017560539A patent/JP6820278B2/ja active Active
- 2016-05-23 CN CN202310981391.9A patent/CN117247944A/zh active Pending
- 2016-05-23 EP EP21187270.0A patent/EP3978521A1/en active Pending
- 2016-05-23 EP EP16799274.2A patent/EP3298038B1/en active Active
- 2016-05-23 US US15/566,555 patent/US20180094047A1/en not_active Abandoned
- 2016-05-23 MA MA042137A patent/MA42137A/fr unknown
-
2018
- 2018-01-08 US US15/864,494 patent/US10544205B2/en active Active
-
2019
- 2019-12-12 US US16/711,861 patent/US11485774B2/en active Active
-
2020
- 2020-07-06 JP JP2020116317A patent/JP7304320B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10544205B2 (en) | 2020-01-28 |
| JP2020171311A (ja) | 2020-10-22 |
| JP6820278B2 (ja) | 2021-01-27 |
| CN107614525A (zh) | 2018-01-19 |
| CN117247944A (zh) | 2023-12-19 |
| EP3298038A4 (en) | 2019-04-24 |
| WO2016188386A1 (en) | 2016-12-01 |
| EP3978521A1 (en) | 2022-04-06 |
| CN113527470A (zh) | 2021-10-22 |
| US20180148496A1 (en) | 2018-05-31 |
| CN113527470B (zh) | 2023-08-25 |
| US11485774B2 (en) | 2022-11-01 |
| RU2017145085A3 (cg-RX-API-DMAC7.html) | 2020-01-23 |
| EP3298038B1 (en) | 2021-08-04 |
| EP3298038A1 (en) | 2018-03-28 |
| US20180094047A1 (en) | 2018-04-05 |
| ES2896275T3 (es) | 2022-02-24 |
| KR102770671B1 (ko) | 2025-02-24 |
| RU2739955C2 (ru) | 2020-12-30 |
| KR20180009780A (ko) | 2018-01-29 |
| JP7304320B2 (ja) | 2023-07-06 |
| US20220275060A9 (en) | 2022-09-01 |
| JP2018519804A (ja) | 2018-07-26 |
| CN107614525B (zh) | 2021-07-06 |
| HK1243429A1 (zh) | 2018-07-13 |
| US20200109186A1 (en) | 2020-04-09 |
| RU2017145085A (ru) | 2019-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
| MA47694A (fr) | Anticorps anti-tigit | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| EP3334757A4 (en) | ANTI-Tigit ANTIBODY | |
| EP3297671A4 (en) | ANTI-ROR1 ANTIBODY | |
| EP3423089A4 (en) | ANTI-Tigit ANTIBODY | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| EP3498840A4 (en) | ANTI-LAG-3 ANTIBODIES | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| PT3354729T (pt) | Anticorpo anti-garp | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| MA47472A (fr) | Anticorps | |
| EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| EP3334824A4 (en) | PD-1 ANTIBODY | |
| PL3556777T3 (pl) | Konstrukty przeciwciał wieloswoistych | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| IL256099A (en) | Antibody | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| IL291164A (en) | Anti-nme antibody | |
| EP3526247A4 (en) | Anti-il1-rap antibodies | |
| EP3399992A4 (en) | SELF-NETWORKING ANTIBODIES | |
| MA42843A (fr) | Anticorps anti-cd115 | |
| EP3617231A4 (en) | ANTI-GPC-1 ANTIBODY |